EP1599440A2 - Chemical process for the preparation of intermediates to obtain n-formyl hydroxylamine compounds - Google Patents
Chemical process for the preparation of intermediates to obtain n-formyl hydroxylamine compoundsInfo
- Publication number
- EP1599440A2 EP1599440A2 EP04713381A EP04713381A EP1599440A2 EP 1599440 A2 EP1599440 A2 EP 1599440A2 EP 04713381 A EP04713381 A EP 04713381A EP 04713381 A EP04713381 A EP 04713381A EP 1599440 A2 EP1599440 A2 EP 1599440A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- compound
- hydrogen
- solvent
- contacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000543 intermediate Substances 0.000 title abstract description 7
- 238000002360 preparation method Methods 0.000 title description 3
- 238000001311 chemical methods and process Methods 0.000 title description 2
- KDGKTJGPFXIBEB-UHFFFAOYSA-N n-hydroxyformamide Chemical class ONC=O KDGKTJGPFXIBEB-UHFFFAOYSA-N 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 52
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 170
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 92
- 239000002904 solvent Substances 0.000 claims description 92
- 239000001257 hydrogen Substances 0.000 claims description 82
- 229910052739 hydrogen Inorganic materials 0.000 claims description 82
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 76
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 46
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 45
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 39
- 239000003054 catalyst Substances 0.000 claims description 37
- -1 tetrafluoroborate Chemical compound 0.000 claims description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 33
- 235000019439 ethyl acetate Nutrition 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 28
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 23
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 239000011541 reaction mixture Substances 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 14
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 14
- 229940011051 isopropyl acetate Drugs 0.000 claims description 14
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 14
- 238000005984 hydrogenation reaction Methods 0.000 claims description 13
- 229910052763 palladium Inorganic materials 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 12
- 239000011707 mineral Substances 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 239000002585 base Substances 0.000 claims description 11
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 11
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 10
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 claims description 10
- 239000012190 activator Substances 0.000 claims description 10
- 235000019253 formic acid Nutrition 0.000 claims description 10
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 239000010948 rhodium Substances 0.000 claims description 9
- 230000003197 catalytic effect Effects 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 7
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 7
- 150000001298 alcohols Chemical class 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 239000007818 Grignard reagent Substances 0.000 claims description 6
- 239000012455 biphasic mixture Substances 0.000 claims description 6
- 150000004795 grignard reagents Chemical class 0.000 claims description 6
- 229910052703 rhodium Inorganic materials 0.000 claims description 6
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 238000010511 deprotection reaction Methods 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 150000004703 alkoxides Chemical class 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 3
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 claims description 3
- BTFSVBAFIHSVBO-UHFFFAOYSA-N dichloromethane;1,4-dioxane Chemical compound ClCCl.C1COCCO1 BTFSVBAFIHSVBO-UHFFFAOYSA-N 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 claims description 3
- 229910052707 ruthenium Inorganic materials 0.000 claims description 3
- 229910052723 transition metal Inorganic materials 0.000 claims description 3
- 150000003624 transition metals Chemical group 0.000 claims description 3
- CAFROQYMUICGNO-UHFFFAOYSA-N 2,2,2-trifluoroethyl formate Chemical compound FC(F)(F)COC=O CAFROQYMUICGNO-UHFFFAOYSA-N 0.000 claims description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- SJYNFBVQFBRSIB-UHFFFAOYSA-N norbornadiene Chemical compound C1=CC2C=CC1C2 SJYNFBVQFBRSIB-UHFFFAOYSA-N 0.000 claims description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 claims description 2
- 125000000532 dioxanyl group Chemical group 0.000 claims 2
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 235000011149 sulphuric acid Nutrition 0.000 claims 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 abstract description 8
- 238000006264 debenzylation reaction Methods 0.000 abstract description 7
- ICBHDGOFKNWYJO-ZCFIWIBFSA-N (2r)-2-(hydroxymethyl)hexanoic acid Chemical compound CCCC[C@H](CO)C(O)=O ICBHDGOFKNWYJO-ZCFIWIBFSA-N 0.000 abstract description 6
- 239000006227 byproduct Substances 0.000 abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 150000004672 propanoic acids Chemical class 0.000 abstract description 3
- 235000019260 propionic acid Nutrition 0.000 abstract description 3
- 150000003952 β-lactams Chemical class 0.000 abstract description 3
- 239000002699 waste material Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 20
- 239000012044 organic layer Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- LLHRMWHYJGLIEV-UHFFFAOYSA-N desoxy Chemical group COC1=CC(CCN)=CC(OC)=C1C LLHRMWHYJGLIEV-UHFFFAOYSA-N 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- ICBHDGOFKNWYJO-UHFFFAOYSA-N 2-(hydroxymethyl)hexanoic acid Chemical compound CCCCC(CO)C(O)=O ICBHDGOFKNWYJO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 239000012973 diazabicyclooctane Substances 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 125000004404 heteroalkyl group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 3
- ICBHDGOFKNWYJO-LURJTMIESA-N (2s)-2-(hydroxymethyl)hexanoic acid Chemical compound CCCC[C@@H](CO)C(O)=O ICBHDGOFKNWYJO-LURJTMIESA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N Butanol Natural products CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- GSNPFCFUDGEFNR-UHFFFAOYSA-N methyl 3-acetyloxy-2-methylidenehexanoate Chemical compound CCCC(OC(C)=O)C(=C)C(=O)OC GSNPFCFUDGEFNR-UHFFFAOYSA-N 0.000 description 3
- YMHOPFPBSLGXDP-UHFFFAOYSA-N methyl 3-hydroxy-2-methylidenehexanoate Chemical compound CCCC(O)C(=C)C(=O)OC YMHOPFPBSLGXDP-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- GMNDSOFHAHEZTD-SUSPOVHDSA-N (2r)-2-(hydroxymethyl)hexanoic acid;(1r)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1.CCCC[C@H](CO)C(O)=O GMNDSOFHAHEZTD-SUSPOVHDSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- QRCHYAAXBFYQKN-UVTDQMKNSA-N CCC\C=C(C(=O)OC)\CNOCC1=CC=CC=C1 Chemical compound CCC\C=C(C(=O)OC)\CNOCC1=CC=CC=C1 QRCHYAAXBFYQKN-UVTDQMKNSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 229940043232 butyl acetate Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- ANFZRGMDGDYNGA-UHFFFAOYSA-N ethyl acetate;propan-2-ol Chemical compound CC(C)O.CCOC(C)=O ANFZRGMDGDYNGA-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- HCKNRHBSGZMOOF-UHFFFAOYSA-N 1-methoxy-2-methylperoxyethane Chemical group COCCOOC HCKNRHBSGZMOOF-UHFFFAOYSA-N 0.000 description 1
- IGGGSAHINVSGTM-UHFFFAOYSA-N 2-ethoxycarbonylhexanoic acid Chemical compound CCCCC(C(O)=O)C(=O)OCC IGGGSAHINVSGTM-UHFFFAOYSA-N 0.000 description 1
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 238000005712 Baylis-Hillman reaction Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- CDKFWIMBZAUBRS-UHFFFAOYSA-M [I-].CC[Mg+] Chemical compound [I-].CC[Mg+] CDKFWIMBZAUBRS-UHFFFAOYSA-M 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000008246 gaseous mixture Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- QUXHCILOWRXCEO-UHFFFAOYSA-M magnesium;butane;chloride Chemical compound [Mg+2].[Cl-].CCC[CH2-] QUXHCILOWRXCEO-UHFFFAOYSA-M 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
- YCCXQARVHOPWFJ-UHFFFAOYSA-M magnesium;ethane;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C YCCXQARVHOPWFJ-UHFFFAOYSA-M 0.000 description 1
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical group COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
- RNTGDZPOEPYOTP-CQSZACIVSA-N methyl (2r)-2-[(phenylmethoxyamino)methyl]hexanoate Chemical compound CCCC[C@@H](C(=O)OC)CNOCC1=CC=CC=C1 RNTGDZPOEPYOTP-CQSZACIVSA-N 0.000 description 1
- RNTGDZPOEPYOTP-AWEZNQCLSA-N methyl (2s)-2-[(phenylmethoxyamino)methyl]hexanoate Chemical compound CCCC[C@H](C(=O)OC)CNOCC1=CC=CC=C1 RNTGDZPOEPYOTP-AWEZNQCLSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002901 organomagnesium compounds Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/20—Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/487—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- This invention is directed to a process for preparing certain antibacterial ⁇ /-formyl hydroxylamine compounds.
- PDF is a metallopeptidase found in prokaryotic organisms, such as bacteria. Protein synthesis in prokaryotic organisms begins with ⁇ /-formyl methionine (fMet). After initiation of protein synthesis, the formyl group is removed by the enzyme PDF; this activity is essential for maturation of proteins. It has been shown that PDF is required for bacterial growth. See Chang et al., J. Bacteriol., Vol. 171 , pp. 4071-4072 (1989); Meinnel et al., J. Bacte ol., Vol. 176, No. 23, pp. 7387-7390 (1994); and Mazel et al., EMBO J., Vol. 13, No. 4, pp. 914-923 (1994). Since protein synthesis in eukaryotic organisms does not depend on fMet for initiation, agents that will inhibit PDF are attractive candidates for development of new anti-microbial and anti-bacterial drugs.
- fMet ⁇ /-formyl methi
- PCT application WO 99/39704 discloses other ⁇ f-formyl hydroxylamine derivatives that are antibacterial agents by virtue of their PDF inhibiting capabilities. Improved processes have been discovered for preparing intermediates useful for preparing these N-[1-oxo-2-alkyl-3- (N-hydroxyformamido)-propyl ⁇ -(carbonylamino-aryl or -heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes, which have one or more of the following features : (1 ) make use of a particular ⁇ -lactam intermediate; (2) which make use of particular resolving agents, e.g., enantiomerically pure substituted propionic acids, especially (R)-2-butyl-3-hydroxy-propionic acid; (3) which avoid the use of hydrogen peroxide (the use of hydrogen peroxide can be a safety concern because of its instability, therefore, this aspect of the invention is safer than the prior art process); and (4) which
- the present invention is directed to the novel processes for preparing certain intermediates which are useful to prepare certain ⁇ /-formyl hydroxylamine compounds which are useful for inhibiting bacteria.
- the present invention is directed to a process for preparing a compound of formula ( IX )
- Step B Contacting the compound of formula ( III ) with hydrogen in the presence of a chiral ligand and a catalytic amount of a hydrogenation catalyst in a suitable solvent and under conditions suitable to form a compound of the formula ( IV )
- Y is a hydroxyl-protecting group such as benzyl
- R is alkyl
- Ac is acetyl; each of R 2 , R 3 , R , R 5 , and R-i 0 and independently is hydrogen or alkyl, or (R 2 or R 3 ) collectively form a C 4- C 7 cycloalkyl
- R' is alkyl or aryl; and n is 0-3, provided that when n is 0, X is -CH 2 -. Furthermore, the present invention discloses process for preparing a compound of formula ( IX ) making use of enantiomerically pure substituted propionic acids, especially (R)-2-butyl-3-hydroxy-propionic acid
- the present invention is directed to a process for preparing a compound of the formula ( X )
- Step 1 comprising Step 1 :
- each of R 2 , R 3 , R ⁇ and R 5 is, independently, hydrogen or alkyl; or R 2 and R 3 , collectively, form a C 4 -C 7 cycloalkyl, provided that R 4 and R 5 are different.
- the present invention discloses process for preparing a compound of formula ( IX ) making use of a two-step process for preparing a compound of formula ( XIII )
- the present invention also provides a process for selectively converting the compound of formula ( VIII ) to the compound of formula ( IX ) by removing the hydroxy-protecting group, preferably benzyl, by contacting the compound of formula ( VIII ) with molecular hydrogen at sub-atmospheric pressures in the presence of a palladium catalyst in ethanol to form the compound of formula ( IX ).
- Another aspect of the present invention is directed to a process for converting the compound of formula ( XXV ) to a compound of formula (XXVI ) by removing hydroxyl- protecting group, preferably benzyl, by contacting the compound of formula ( XXV ) with a hydrogen transfer reagent comprising 4-methylmorpholine and formic acid in the presence of a palladium catalyst.
- Steps A-F the present invention is directed to each of the steps individually, and to any two or more sequential steps.
- the present invention provides a process for preparing intermediates useful in the preparation of a A/-[1-oxo-2-alkyl-3-(A/-hydroxyformamido)propyl]- (carbonylamino-aryl or -heteroaryl)-azacyclo 4-7 alkanes or thiazacyclo 4-7 alkanes, e.g., a compound of formula ( IX )
- R 1 ; R 2 , R 3 , R 4 , R*, X and n are as defined above.
- Step F can be performed wherein the hydroxyl-protecting group is removed using conventional hydrogenation techniques known in the art, e.g., by contacting the compound of formula ( VIII ) with hydrogen in the presence of a palladium catalyst, such as Pd/BaS0 .
- a palladium catalyst such as Pd/BaS0 .
- Ri is a heteroaryl of formula ( 11.1 )
- R 6 , R 7 and R 9 are hydrogen; and R 8 is methyl or trifluoromethyl; or
- R 6 , R and R 8 are hydrogen; and R 9 is fluoro; or
- R 6 , R 8 and R 9 are hydrogen; and R 7 is ethyl or methoxy; or
- R 7 , R 8 and R 9 are hydrogen; and R 6 is hydroxy; or
- R 7 and R 8 are hydrogen; R 6 is methoxy; and R 9 is methyl; or
- R 1 is a heteroaryl of formula ( 111.1 )
- R 6 , R 7 and R 9 are hydrogen; and R 8 is fluoro or trifluoromethyl; or
- R 6 , R 8 and R 9 are hydrogen; and R 7 is ethyl; preferably R-i is a heteroaryl of formula ( 11.1 ), wherein
- R 6 , R 8 and Rg are hydrogen
- R 7 is ethyl
- R-i is a heteroaryl of formula ( II 1.1 ), wherein
- R 6 , R and R 9 are hydrogen; and R 8 is fluoro.
- X is -CH 2 -, -CH(OH)-, -CH(OR)-, -CF 2 - or -CH(F)-, preferably X is -CH 2 -;
- R 2 , R3, R5 are hydrogen
- R 4 and R 10 are alkyl, preferably alkyl for R 10 such as n-propyl;
- n 1.
- alkyl refers to saturated aliphatic groups, including cycloalkyl or substituted alkyl, preferably straight-chain, branched-chain and cyclic groups having from 1- 10 carbons atoms. More preferably, "alkyl” or “alk”, whenever it occurs, is a C ⁇ .C 7 alkyl, particularly, C ⁇ alkyl.
- alkyl or “alk” include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, -butyl, n-pentyl, neopentyl, n-hexyl or n-heptyl, cyclopropyl and especially n-butyl.
- cycloalkane or "cycloalkyl” contains from 3- to 7-ring carbon atoms, and is, e.g., cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- aryl refers to an aromatic carbocyclic group of 6-14 carbon atoms having a single ring including, but not limited to, groups, such as phenyl; or multiple condensed rings including, but not limited to, groups, such as naphthyl or anthryl; and, is especially, phenyl.
- heteroaryl refers to a 4- to 7-membered, monocyclic aromatic heterocycle or a bicycle that is composed of a 4- to 7-membered, monocylic aromatic heterocycle and a fused-on benzene ring.
- the heteroaryl has at least one hetero atom, preferably one or two heteroatoms including, but not limited to, heteroatoms, such as N, O and S, within the ring.
- a preferred heteroaryl group is pyridinyl, pyrimidinyl or benzdioxolanyl.
- the aryl or heteroaryl may be substituted or unsubstituted by one or more substituents including, but not limited to, C C 7 alkyl, particularly, C C 4 alkyl, such as methyl, hydroxy, alkoxy, acyl, acyloxy, SCN, halogen, cyano, nitro, thioalkoxy, phenyl, heteroalkylaryl, alkylsulfonyl and formyl.
- substituents including, but not limited to, C C 7 alkyl, particularly, C C 4 alkyl, such as methyl, hydroxy, alkoxy, acyl, acyloxy, SCN, halogen, cyano, nitro, thioalkoxy, phenyl, heteroalkylaryl, alkylsulfonyl and formyl.
- heteroalkyl refers to saturated or unsaturated Ci.doalkyl as defined above and, especially, C ⁇ C ⁇ eteroalkyl which contain one or more heteroatoms, as part of the main, branched or cyclic chains in the group.
- Heteroatoms may independently be selected from the group consisting of -NR-, where R is hydrogen or alkyl, -S-, -O- and -P-; preferably -NR-, where R is hydrogen or alkyl; and/or -O-.
- Heteroalkyl groups may be attached to the remainder of the molecule either at a heteroatom (if a valence is available) or at a carbon atom.
- heteroalkyl groups include, but are not limited to, groups, such as -O-CH 3 , -CH 2 -O-CH 3 , -CH 2 -CH 2 -O-CH 3 , -S-CH 2 -CH 2 -CH 3 , -CH 2 -CH(CH 3 )-S-CH 3 and -CH2-CH2-NH-CH2-CH2-.
- alkoxy refers to a C ⁇ C ⁇ alkyl linked to an oxygen atom, or preferably, C ⁇ .C 7 alkoxy, more preferably, C ⁇ .C 4 alkoxy.
- alkoxy groups include, but are not limited to, groups such as methoxy, ethoxy, n-butoxy, terf-butoxy and allyloxy.
- acyl refers to the group -(O)CR, where R is alkyl, especially, C ⁇ C T -alkyl, such as methyl.
- R alkyl
- C ⁇ C T -alkyl such as methyl.
- acyl groups include, but are not limited to, acetyl, propanoyl and butanoyl.
- acyloxy refers to the group -OC(0)R, wherein R is hydrogen, alkyl, especially, C ⁇ .C 7 alkyl, such as methyl or ethyl, or phenyl or substituted alkyl as defined above.
- alkoxycarbonyl refers to the group -COOR, wherein R is alkyl, especially, C ⁇ .C 7 alkyl, such as methyl or ethyl.
- halogen or "halo” as used herein, refers to chlorine, bromine, fluorine, iodine and, is especially, fluorine.
- thioalkoxy means a group -SR, where R is an alkyl as defined above, e.g., methylthio, ethylthio, propylthio, butylthio and the like.
- heteroalkylaryl means a heteroalkyl group, e.g., -O-CH 2 - substituted with an aryl group, especially, phenyl.
- the phenyl group itself may also be substituted with one or more substituents, such as halogen, especially fluoro and chloro; and alkoxy, such as methoxy.
- alkylsulfonyl means a group -SO 2 R, wherein R is alkyl, especially, d.C 7 alkyl, such as methyl sulfonyl.
- enantiomericly pure or “optically pure” means that the enantiomeric purity is greater than 55%, preferably greater than 80%, more preferably greater than 90%, and most preferably greater than 95%.
- the above reaction is a Baylis-Hillman reaction.
- the compound thus formed can then be reacted with acetic anhydride in a suitable solvent, in the presence of a base, such as 4-DMAP or a trialkylamine, e.g., triethylamine or tripropylamine, to form the compound of formula ( I ).
- a base such as 4-DMAP or a trialkylamine, e.g., triethylamine or tripropylamine, to form the compound of formula ( I ).
- R 2 and R 3 are hydrogen and R is n-propyl; which results in a compound such as formula ( lc )
- the solvent used for the various steps A-F are typically organic solvents, although in some situations, aqueous/organic solvents can be used.
- suitable solvents include dioxane, methylene chloride, dichloromethane, toluene, acetone, methylethylketone, THF, isopropyl acetate, DMF, alcohols, especially higher-branched alcohols, such as i- butanol and the like.
- a typical temperature is about 10°C to about 50°C, preferably about 20°C to about 25°C.
- the solvent for Step A is typically THF, DMF, NMP and the like.
- a typical temperature is about 10°C to about 50°C, preferably about 20°C to about 25°C.
- the solvent for Step B is not known to be critical and can be a wide variety of solvents, such as dioxane, methylene chloride, dichloromethane, toluene, acetone, methylethylketone, THF, isopropyl acetate, DMF, alcohols, especially higher-branched alcohols, such as f-butanol and the like.
- the hydrogen for Step is typically in the form of hydrogen gas and the Step B is typically preformed above atmospheric pressure, e.g., at about 40 psi to about 100 psi, more typically at about 45 psi to about 55 psi.
- the chiral ligand for Step B can be (2S,5S)-Me-Duphos, (1R, 1'R,2S,2'S)- TangPhos and the like. (1R,1'R,2S,2'S)-TangPhos has the formula
- the amount of Chiral ligand is typically about 1 mole % to about 15 mole % relative to the substrate.
- the hydrogenation catalyst is preferably homogenous.
- the hydrogenation catalyst is preferably a transition metal complex. Typical transition metal catalysts contain rhodium (Rh I) or ruthenium (Ru II).
- a preferred catalyst is fe/s(norbomadiene)rhodium(l) tetrafluoroborate.
- the amount of catalyst is a catalytic amount, typically about 1 mole % to about 5 mole % relative to the substrate.
- a typical temperature is about -10°C to about 20°C, preferably about 0°C.
- the pH for Step C is basic, typically, about 8 pH to about 12 pH.
- the Grignard reagent used in Step C can be any suitable organomagnesium compound known in the art, such as methylmagnesium chloride, ethylmagnesium chloride, isopropyl magnesium chloride, n-butylmagnesium chloride, methylmagnesium bromide, isopropylmagnesium bromide, cyclopropylmagnesium bromide, ethylmagnesium iodide and the like.
- the amount of Grignard reagent employed is a de-protonating amount which is typically in molar excess to the amount of formula ( IV ), e.g., about 1-5 equivalents relative to formula ( IV ).
- a preferred solvent is acetone or methylethylketone.
- a typical temperature is about 30°C to about 150°C, preferably about 60°C to about 80°C.
- the pH for Step D is typically about 5 pH to about 11 pH.
- the activator for Step D is a compound which protonates the ⁇ -lactam keto oxygen; such activators include, e.g., mild (weak) organic acids, such as branched or unbranched carboxylic acids, e.g., 2-ethylhexanoic acid, acetic acid, isobutryic acid and the like. If an aqueous alcoholic solvent is used an activator is not needed; preferred aqueous alcoholic solvents include MeOH ⁇ 2 0, EtOH ⁇ 2 O and the like.
- a preferred solvent is THF, dioxane or dimethoxyethane. If an activator is used it is used in an protonating amount which is typically about 0.1 molar equivalents to about 2 molar equivalents relative to formula ( V ).
- a typical temperature is about -30°C to about 50°C, preferably about 0°C to about 25°C.
- the pH for Step E is not critical and can vary considerably.
- the solvent should not be an alcoholic solvent.
- the formylating agent can be, e.g., HCO 2 H/Ac 2 0, trifluoroethylformate and the like, and is present in a formylating amount which is typically about 1 molar equivalent to about 2 molar equivalents relative to formula ( VII ).
- a preferred solvent is EtOAc, isopropylacetate, f-butylacetate or THF.
- Step B will comprise:
- R 4 is n-butyl, where such compound has the formula ( Xb )
- R 2 , R 3 and R 5 are hydrogen and that R 4 is n-butyl where such compound has the structure ( Xc ):
- Step 2 it is preferred to re-crystallize the diasteriomeric salt from a suitable solvent, preferably from the same solvent system, prior to performing the second step (step 2).
- a preferred process of the invention comprises resolution of a compound of formula ( IXa ) by contacting said compound with (f?)- ⁇ -methylbenzylamine in a mixture of ethyl acetate and 2-propanol to form a compound of formula ( Ilia )
- Step 3 a third step (Step 3) is performed wherein the compound formed by the second step, i.e., the compound of formula ( X ), is contacted with a compound of the formula ( XIX )
- R' is alkyl or aryl and X' is halo, in the presence of a base in a suitable solvent, under conditions suitable to form a compound of the formula ( XXII )
- Step 8 converting the compound of formula ( XXIV ) to the compound of formula ( IX ) by removing the hydroxy-protecting group using conventional hydrogenation techniques known in the art, e.g., by contacting the compound of formula ( XXIV ) with hydrogen in the presence of a palladium catalyst, such as Pd/BaSO 4 , to form the compound of formula ( IX )
- a palladium catalyst such as Pd/BaSO 4
- the (S) enantiormer can be prepared instead of the (R) enantiomer by using the (S) form of the resolving agent rather than the (R) form.
- Such a process comprises preparing a compound of the formula ( X' )
- Pressure is not known to be critical for carrying out the various steps 1 - 8 and 1 ' -2' of the invention.
- a temperature of about -10°C to about 150°C, preferably about 0°C to about 80°C, is typically employed.
- atmospheric pressure is used for convenience; however, variations to atmospheric pressure are not known to be detrimental.
- Oxygen is not known to be detrimental to the process, therefore for convenience, the various steps can be performed under ambient air, although an inert atmosphere, such as nitrogen or argon, can be used if desired.
- equimolar amounts of reactants are typically used; however, molar ratios can vary from about 1-2 equivalents, relative to the other reactant.
- the pH for most steps is typically about 2 pH to about 12 pH, although, as mentioned below, the pH for Step 2 must be very acidic.
- the solvent to be used for the various steps will depend on the nature of the reactants and other conditions and can be, e.g., ethyl acetate, isopropyl acetate, toluene, dichloromethane dioxane, methylene chloride, toluene, acetone, methylethylketone, THF, DMF, alcohols and the like; however, the solvents for Steps 1 and 2 are listed below.
- a typical temperature is about 10°C to about 90°C.
- the reaction mixture is initially heated to about 50°C to about 90°C, and then cooled to crystallize the desired compound, e.g., at a temperature of about 10°C to about 40°C.
- the amount of resolving agent, i.e., (R)- ⁇ -methylbenzylamine, employed is typically about 0.7 molar equivalents to about 1.5 molar equivalents relative to formula ( XI ).
- the solvent for Step 1 is a mixture of an ester or an alkyl nitrile and an alcohol.
- esters include, e.g., alkyl acetates, such as isopropyl acetate, -butyl acetate, ethyl acetate and the like.
- alkyl nit les include, e.g., acetonitrile and the like.
- alcohols include methanol, ethanol, isopropanol and the like.
- the ratio of ester or alkyl nitrile to alcohol can vary from about 90:10 to about 10:90, preferably about 75:25 to about 25:75, and most preferably about 50:50, the preceding ratios being based on volume:volume.
- the most preferred solvent is a mixture of ethyl acetate:2-propanol (50:50, vohvol).
- a typical temperature is about 10°C to about 30°C, preferably about 20°C to about 25°C.
- the pH for Step 2 is acidic and is typically about a pH of 1 or less.
- the solvent for step 2 is a mixture of an aqueous mineral acid and an organic solvent which forms a biphasic solvent comprising and aqueous and organic phases.
- the ratio (volume:volume) of aqueous mineral acid:organic solvent can vary widely, e.g., 90:10-10:90, more typically 60:40-40:60.
- the desired compound of formula ( X ) can be recovered from the organic phase using conventional purificati oi n and/or separation techniques known in the art such as distillation, filtration and the ke.
- aqueous inorganic salt solution such as a 10-40% by weight aqueous solution of sodium chloride. Strong mineral acids are typically used for
- Step 2 e.g., HCI, H 2 S0 4 and the like.
- the strength of the acid is strong enough for forming the desired compound, typically about 1 N to about 6 N, with about 2 N being preferred.
- the organic solvent can be ethyl acetate, isopropyl acetate, toluene, dichloromethane dioxane, methylene chloride, toluene, acetone, methylethylketone, THF, DMF and the like.
- the alkoxide of p-methoxybenzyl alcohol can be formed in situ by contacting p-methoxybenzyl alcohol with an organic base such as LiHMDS, NaHMDS, and the like.
- the solvent for Step i can be, for example, diethyl ether, DMF, NMP, THF and the like.
- the temperature for Step i is not known to be critical and can vary from about 10°C to about 40°C and, for convenience, is typically preferred at RT, e.g., about 20°C to about 25°C.
- the strong organic acid can be formic acid, p-toluenesulfonic acid, and the like.
- the acid typically solubilizes the compound of formula ( XV ), and therefore serves as the solvent for the reaction.
- the amount of acid is, therefore sufficient to solubilize and deprolect the compound of formula ( XV ).
- the temperature for Step ii is not known to be critical and can vary from about 10°C to about 40°C and, for convenience, is typically preferred at RT, e.g., about 20°C to about 25°C.
- the desired products can be purified and concentrated using conventional techniques known in the art.
- a mixture of ethyl acetate and aqueous acid or base can be added to the reaction mixture to form a biphasic solution wherein the desired product will be in the organic phase.
- Typical acids for this use are strong mineral acids such as HCI, H 2 S0 4 , and the like, and typical bases are sodium carbonate, and the like.
- Removal of the solvent can be accomplished using conventional techniques, e.g., distillation under reduced pressure. Further purification of the desired product can also be preformed, e.g., using chromatography such as flash chromatography, HPLC, and the like.
- another aspect of the present invention provides a novel process for preparing active anti-bacterial compounds of formula (IX) by treatment the compounds of formula (VIII) with hydrogen at sub-atmospheric partial pressures in the presence of a palladium catalyst in ethanol.
- the present process minimizes production of by-product, thereby resulting in a process that is environmentally benign.
- the reaction may be carried out by sparging a gaseous mixture of hydrogen and nitrogen at 1 atm total pressure in a reaction mixture containing compound of formula (VIII), ethanol and a palladium catalyst, e.g., palladium on carbon.
- the desired hydrogen partial pressure is attained by varying the relative flow rate of nitrogen and hydrogen. A reasonable reaction time is required, i.e., the reaction is allowed to proceed until the desired product is formed.
- Another aspect of the present invention is directed to a process for preparing a compound of formula ( IX )
- R 1 is aryl or heteroaryl, preferably
- each of R 2 , R 3 ,R 4 and R 5 independently is hydrogen or alkyl, or (R 2 or R 3 ) collectively form a C -C 7 cycloalkyl, preferably R 2 , R 3 , R 5 are hydrogen and R 4 is n-butyl; n is 0-3, preferably 1.
- Y is a hydroxy-protecting group, preferably benzyl, to the compound of formula ( IX ) by removing the hydroxyl-protecting group by contacting the compound of formula ( XXV ) with molecular hydrogen at hydrogen partial pressures below 1 atm, preferably about 0.1 atm to about 0.24atm , while maintaining a total pressure of about 1atm in the presence of a palladium catalyst, such as 5% Pd/C, in a suitable solvent, preferably ethanol, at about 10 to about 30 °C , typically about 20°C.
- a palladium catalyst such as 5% Pd/C
- Another aspect of the present invention is selective O-debenzylation in the presence of pyridine N-oxides via hydrogen transfer using formic acid/4-methylmorpholine.
- the penultimate step of a synthesis of the compound of formula ( IX ) comprises a catalytic removal of hydroxy-protectng group by contacting the compound of formula ( XXV) with hydrogen in the presence of a catalyst such as Pd/C.
- the compound of formula ( XXV ) may include a pyridine N-oxide group; when the removal of hydroxy-protecting group is carried out at typical conditions (e.g., hydrogen partial pressures at or above 1atm) hydrogenolysis of the N-0 bond in the pyridine N-oxide occures to a significant extent, resulting in production of by product in significant amounts.The latter is difficult to separate.
- the deprotection can be carried out selectively via hydrogen transfer instead of using molecular hydrogen.
- a means has been found to conduct deprotection very selectively with a hydrogen transfer reagent comprising 4-methylmorpholine and formic acid.
- a hydrogen transfer reagent comprising 4-methylmorpholine and formic acid.
- Such chemical transformatin occurs at elevated temperatures, preferably reaction mixture is being heated at about 45°C for about 25 ⁇ 10 min.
- Mem methoxy ethoxy methyl ether
- NPEOC 4-nitrophenethyloxycarbonyl
- NPEOM 4-nitrophenethyloxy-methyloxycarbonyl
- Ph phenyl
- the reaction mixture is concentrated on Rotavap under reduced pressure (20 mbar) until no further solvent distills.
- the residue liquid is dissolved in a mixture of ethyl acetate/heptane (50/50, 10 mL) and filtered through a silica gel pad (-12 g).
- the silica gel pad is rinsed with a mixture of ethyl acetate/heptane (50/50, 200 mL).
- a 12 L, 4-necked, round-bottomed flaks, equipped with a mechanical stirrer, digital thermometer, and nitrogen inlet-outlet is charged with 2-butyl-propanedioic acid monoethyl ester (3, 450.0 g, 2.39 mol) and isopropanol (4.5 L).
- the solution is cooled to an internal temperature at 15-18°C and a 2 M solution of lithium borohydride (2.4 L, 4.8 mol) in tetrahydrofuran is added over a period of 1.5 hours while maintaining the internal temperature at 15-25°C.
- the stirring is continued for an additional 3 h.
- the reaction mixture is cooled to an internal temperature at 10-13°C and quenched by the addition of 2 N HCI (2.4 L) over a period of 1 hour while maintaining the internal temperature at 10-25°C.
- the reaction mixture is concentrated at 35-40°C (20 mbar) to collect -7.5 L of the solvent to obtain a suspension (-1.9 kg).
- This suspension is diluted with water (2.0 L) and ethyl acetate (2.5 L) and the biphasic mixture is stirred for 1 hour.
- the organic layer is separated and the aqueous layer is extracted with ethyl acetate (2.0 L).
- the addition funnel is washed with ethyl acetate (0.2 L) and added to the mixture.
- the solution is cooled to 20-25°C over a period of 2 hours and the resulting suspension is stirred at the same temperature for an additional 5 hours.
- a means to operate at subatmospheric H 2 partial pressures while maintaining a total pressure of 1 atmospheric was achieved (thus obviating solvent evaporation and leaks) by performing the reaction using H 2 diluted with N 2 ).
- the apparatus comprises two calibrated mass flow controllers, one for N 2 and the other for H 2 , which allow for a controlled flow rate of each gas based on an inputted set point. By varying the relative flow rates of the two gases, any H 2 partial pressure can be achieved.
- a 250-mL jacketed vessel equipped with a gassing agitator is charged with 8 g of C9, 62 g (-80 mL) of 200-proof ethanol, and 1.3 g of 5% Pd/C catalyst (Degussa, E1070 NO 5% Pd, water content 66.2 of wt %, Lot # 6JLG30), or 0.44 g of catalyst on a dry basis.
- the headspace is purged of air by flowing N 2 through both mass flow controllers at about 30 cm 3 /min.
- the reactor is kept open to the atmospheric, giving a pressure of 1 atm in the vessel.
- the reaction is started by setting flow rates of 28 and 9 cm 3 /min, respectively, on the N 2 and H 2 mass flow controllers, giving a H 2 partial pressure of 0.24 atm.
- a 700 rpm agitation rate is used, and the reaction temperature is 20°C.
- the lower hydrogen concentration in the liquid-phase gives a slower reaction, with the time required for 100% C9 conversion being about 3 h vs. 1.7 h for the 1-atm H 2 partial pressure case.
- a significant des-oxy C10 selectivity advantage is observed at 0.24 H 2 partial pressure.
- a 0.99% des-oxy C10 yield is obtained at 97.6% C9 conversion, giving a selectivity of 1.01% vs. a des-oxy C10 yield of 6.07% at 99.8% C9 conversion, giving a selectivity of 6.1%, in the 1-atm case.
- Example 15 Debenzylation at a hydrogen partial pressures of 0.1 atm:
- a 250-mL jacketed vessel equipped with a gassing agitator is charged with 8 g of C9, 62 g (-80 mL) of 200-proof ethanol, and 1.4 g of 5% Pd/C catalyst (Degussa, E1070 NO 5% Pd, water content 68.05 of wt %, Lot # CC1-2215), or 0.45 g of catalyst on a dry basis.
- the headspace is purged of air by flowing N 2 through both mass flow controllers at about 30 cm 3 /min.
- the reactor is kept open to the atmospheric, giving a pressure of 1 atm in the vessel.
- the reaction is started by setting flow rates of 28 and 3 cm 3 /min, respectively, on the N 2 and H mass flow controllers, giving a H partial pressure of 0.1 atm.
- a slower reaction is obtained relative to the 0.24 H 2 partial pressure case (4.5 vs. 3 h), but the reaction is not unreasonably long for a production process.
- Even more favorable des-oxy C10 selectivities are obtained at 0.1 atm H 2 partial pressure, viz., 0.78% des-oxy C10 yield at 99.8% C9 conversion, giving a des-oxy C10 selectivity of 0.78% vs. a 0.99% des-oxy C10 yield at 97.6% C9 conversion, giving a selectivity of 1.01%, for the 0.24-atm H 2 partial pressure case.
- Example 16 makes reference to reaction scheme below:
- a jacketed vessel is charged with 169.85 mmol solution of C9 in ethanol, 27.497 g of 4- methylmorpholine and 138.0 g of 200-proof ethanol. After stirring reaction mixture at about 22°C 10.845 g of formic acid is added at a rate to maintain 22°C following by addition of 69. Og of 200-proof ethanol. 8.016 g of 10%Pd/C are added to the reaction following by addition of 44.28 g of 200-proof ethanol. Mixture is heated to about 45°C for a period 25 ⁇ 10min. Batch is held at this temperature for 2-3 hours. Filtered and twice washed with ethanol yielding C10.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44901503P | 2003-02-21 | 2003-02-21 | |
| US44901603P | 2003-02-21 | 2003-02-21 | |
| US44901703P | 2003-02-21 | 2003-02-21 | |
| US449015P | 2003-02-21 | ||
| US449016P | 2003-02-21 | ||
| US449017P | 2003-02-21 | ||
| PCT/US2004/005159 WO2004076053A2 (en) | 2003-02-21 | 2004-02-20 | Chemical process for the preparation of intermediates to obtain n-formyl hydroxylamine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1599440A2 true EP1599440A2 (en) | 2005-11-30 |
Family
ID=32931324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP04713381A Withdrawn EP1599440A2 (en) | 2003-02-21 | 2004-02-20 | Chemical process for the preparation of intermediates to obtain n-formyl hydroxylamine compounds |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7452999B2 (en) |
| EP (1) | EP1599440A2 (en) |
| JP (1) | JP2006519786A (en) |
| CN (2) | CN101092342A (en) |
| AU (1) | AU2004216178B2 (en) |
| BR (1) | BRPI0407448A (en) |
| CA (1) | CA2516465A1 (en) |
| MX (1) | MXPA05008842A (en) |
| PL (1) | PL379008A1 (en) |
| WO (1) | WO2004076053A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1406893B1 (en) | 2001-06-15 | 2007-04-18 | Vicuron Pharmaceuticals, Inc. | Pyrrolidine bicyclic compounds |
| ES2321504T3 (en) | 2002-09-19 | 2009-06-08 | Novartis Ag | PROCESS FOR THE PREPARATION OF INTERMEDIATE PRODUCTS. |
| AU2004216178B2 (en) | 2003-02-21 | 2008-07-03 | Novartis Ag | Chemical process for the preparation of intermediates to obtain N-formyl hydroxylamine compounds |
| GT200600196A (en) * | 2005-05-23 | 2007-01-15 | N-FORMIL HYDROXYLAMINE COMPOUNDS | |
| MX2008011128A (en) * | 2006-03-03 | 2008-09-08 | Novartis Ag | N-formyl hydroxylamine compounds. |
| CN101584694B (en) * | 2009-06-15 | 2011-01-12 | 华东师范大学 | Peptide deformylase inhibitor containing 2, 5-dihydropyrrole and synthesizing method |
| EA026338B1 (en) | 2009-08-28 | 2017-03-31 | Лонца Аг | Method for preventing plugging of a channel-system in a micro-reactor and micro-reactor for carrying out the method |
| CN103998421A (en) * | 2011-12-19 | 2014-08-20 | 住友化学株式会社 | Racemization method of α-substituted-β-amino acid esters |
| CN114685277A (en) * | 2020-12-31 | 2022-07-01 | 苏州瑞博生物技术股份有限公司 | Compound and method for purifying hydroxypropionate compound |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5543052A (en) * | 1978-09-22 | 1980-03-26 | Sumitomo Chem Co Ltd | Preparation of optically active gamma hydroxynonanoic acid |
| JPH01175956A (en) * | 1988-01-04 | 1989-07-12 | Muraki Buhin Kk | Purification of optically pure 3-hydroxy acids |
| JP4218040B2 (en) * | 1997-12-26 | 2009-02-04 | 曽田香料株式会社 | Process for producing complex salt of organic acid and amine |
| EP1052984B1 (en) * | 1998-02-07 | 2004-05-12 | Vernalis (Oxford) Ltd | Antibacterial agents |
| WO2001034612A2 (en) * | 1999-11-10 | 2001-05-17 | The Penn State Research Foundation | Chiral phosphines, transition metal complexes thereof and uses thereof in asymmetric reactions |
| US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
| US6852752B2 (en) * | 1999-12-17 | 2005-02-08 | Vicuron Pharmaceuticals Inc. | Urea compounds, compositions and methods of use and preparation |
| EP1406893B1 (en) * | 2001-06-15 | 2007-04-18 | Vicuron Pharmaceuticals, Inc. | Pyrrolidine bicyclic compounds |
| AR036053A1 (en) * | 2001-06-15 | 2004-08-04 | Versicor Inc | N-FORMIL-HYDROXYLAMINE COMPOUNDS, A PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS |
| ES2321504T3 (en) | 2002-09-19 | 2009-06-08 | Novartis Ag | PROCESS FOR THE PREPARATION OF INTERMEDIATE PRODUCTS. |
| AU2004216178B2 (en) | 2003-02-21 | 2008-07-03 | Novartis Ag | Chemical process for the preparation of intermediates to obtain N-formyl hydroxylamine compounds |
| TW200427458A (en) | 2003-04-02 | 2004-12-16 | Novartis Ag | Crystalline N-formyl hydroxylamine compounds |
| EP1641778A1 (en) | 2003-06-26 | 2006-04-05 | Novartis AG | Process for preparing intermediates useful to prepare certain antibacterial n-formyl hydroxylamines |
-
2004
- 2004-02-20 AU AU2004216178A patent/AU2004216178B2/en not_active Ceased
- 2004-02-20 WO PCT/US2004/005159 patent/WO2004076053A2/en not_active Ceased
- 2004-02-20 CN CNA2007101361312A patent/CN101092342A/en active Pending
- 2004-02-20 US US10/544,919 patent/US7452999B2/en not_active Expired - Fee Related
- 2004-02-20 BR BR0407448-3A patent/BRPI0407448A/en not_active IP Right Cessation
- 2004-02-20 JP JP2006503764A patent/JP2006519786A/en active Pending
- 2004-02-20 PL PL379008A patent/PL379008A1/en unknown
- 2004-02-20 EP EP04713381A patent/EP1599440A2/en not_active Withdrawn
- 2004-02-20 CN CNA200480006326XA patent/CN1759097A/en active Pending
- 2004-02-20 MX MXPA05008842A patent/MXPA05008842A/en active IP Right Grant
- 2004-02-20 CA CA002516465A patent/CA2516465A1/en not_active Abandoned
-
2008
- 2008-11-17 US US12/272,552 patent/US20090131707A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2004076053A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004216178B2 (en) | 2008-07-03 |
| CN1759097A (en) | 2006-04-12 |
| PL379008A1 (en) | 2006-06-26 |
| WO2004076053A3 (en) | 2004-12-02 |
| CN101092342A (en) | 2007-12-26 |
| US20090131707A1 (en) | 2009-05-21 |
| JP2006519786A (en) | 2006-08-31 |
| WO2004076053A2 (en) | 2004-09-10 |
| MXPA05008842A (en) | 2005-10-05 |
| US7452999B2 (en) | 2008-11-18 |
| BRPI0407448A (en) | 2006-01-31 |
| CA2516465A1 (en) | 2004-09-10 |
| AU2004216178A1 (en) | 2004-09-10 |
| US20070179298A1 (en) | 2007-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090131707A1 (en) | Chemical process for the preparation of intermediates to obtain n-formyl hydroxylamine compounds | |
| US20060199958A1 (en) | Process and intermediates for the preparation of pyrrolidine carboxylic acids | |
| CZ384697A3 (en) | Process for preparing (s)-3-(aminomethyl)-5-methylhexanes | |
| JPWO1996023756A1 (en) | Method for producing α-haloketones, α-halohydrins and epoxides | |
| WO2011148392A1 (en) | Process for the preparation of (2s,4s,5s,7s)-n-(2-carbamyl-2- methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3- methoxypropoxy)phenyl]-octanamide hemifumarate and its intermediates thereof | |
| KR20040084915A (en) | Novel boronate esters | |
| ITMI951073A1 (en) | PROCEDURE FOR THE PREPARATION OF [R- (R *)] - 5- (3-CHLOROPHENYL) -3- [2- (3,4-DIMETOXYPHENYL) -1-METHYL] -OSSAZOLIDIN-2-ONE " | |
| EP0614986B1 (en) | Enzymatic racemate cleavage of 2-pipéridine alkylcarboxylates | |
| KR100915551B1 (en) | Method for efficiently preparing 3-hydroxy pyrrolidine and derivatives thereof | |
| JP4108611B2 (en) | Method for producing (R) -3-hydroxy-3- (2-phenylethyl) hexanoic acid | |
| EP2448916B1 (en) | Production of trans-4-aminocyclopent-2-ene-1-carboxylic acid derivatives | |
| MXPA05003089A (en) | Process for preparing intermediates. | |
| JP2986464B2 (en) | Method for producing chiral succinic acid derivative | |
| WO2005121117A1 (en) | Processes for production of optically active compounds | |
| JP4030289B2 (en) | Process for producing β-ketonitriles | |
| US6838527B2 (en) | Polymer-immobilized α-iminoester | |
| KR920000953B1 (en) | Method for preparing optically active 3.4-dihydroxy butyric acid derivatives | |
| JP3539152B2 (en) | Production of cytosine | |
| JPH10306053A (en) | Production of ester | |
| JP2006312644A (en) | Process for producing β-ketonitriles | |
| JP2001151745A (en) | METHOD FOR PRODUCING 3-NITRO-2-(N-t-BUTOXYCARBONYL)- AMINOBENZOATES AND INTERMEDIATE FOR PRODUCING THE SAME ESTERS | |
| JP3439797B2 (en) | Method for producing amine derivative | |
| JPH08208587A (en) | Method for purifying N, O-dialkylhydroxamic acid and O-alkylhydroxamic acid | |
| JPH0717929A (en) | Process for producing N, O-dialkylhydroxylamine | |
| JP2006036707A (en) | Method for producing tetrahydropyranyl-4-carboxylate compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20050921 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| DAX | Request for extension of the european patent (deleted) | ||
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NOVARTIS PHARMA GMBH Owner name: NOVARTIS AG |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1086252 Country of ref document: HK |
|
| 17Q | First examination report despatched |
Effective date: 20091117 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20100330 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1086252 Country of ref document: HK |